Table 3 Comparison of baseline characteristics between revascularized and non-revascularized patients
All (n = 830) | Death (n = 604) | ESKD (n = 172) | CVE (n = 310) | Any (n = 682) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Non-revascularized (n = 685) | Revascularized (n = 145) | p | Non-revascularized (n = 504) | Revascularized (n = 100) | p | Non-revascularized (n = 138) | Revascularized (n = 34) | p | Non-revascularized (n = 242) | Revascularized (n = 68) | p | Non-revascularized (n = 557) | Revascularized (n = 125) | p | |
Median age (years) | 71.6 (65.1–77.3) | 69.2 (63.3–74.6) | 0.001 | 72.1 (67.1–78.1) | 69.5 (65.2–75.1) | 0.002 | 70.4 (64.1–75.3) | 68.5 (62.6–75.8) | 0.4 | 71.3 (65.2–76.7) | 68.5 (62.8–73.1) | 0.007 | 71.9 (66.4–77.4) | 69.2 (64.0–64.5) | <0.0001 |
Male (%) | 61.2 | 53.8 | 0.1 | 61.5 | 53.0 | 0.1 | 64.5 | 58.8 | 0.5 | 64.0 | 58.8 | 0.4 | 61.2 | 56.8 | 0.4 |
RAS >70% unilateral (%) | 38.2 | 45.5 | 0.1 | 40.5 | 45.0 | 0.4 | 42.8 | 41.2 | 0.9 | 35.1 | 39.7 | 0.5 | 39.7 | 44.0 | 0.4 |
RAS >70% Bilateral (%) | 6.6 | 29.7 | <0.0001 | 7.3 | 30.0 | <0.0001 | 7.2 | 29.4 | <0.0001 | 5.8 | 27.9 | <0.0001 | 7.5 | 28.8 | <0.0001 |
Median patency score | 110.0 (90.0–150.0) | 75.0 (40.0–120.0) | <0.0001 | 100.0 (80.0–150.0) | 72.5 (40.0–115.0) | <0.0001 | 100.0 (73.8–150.0) | 82.5 (40.0–120.0) | 0.005 | 120.0 (80.0–150.0) | 75.0 (40.0–110.0) | <0.0001 | 105.0 (132.0–172.5) | 75.0 (40.0–120.0) | <0.0001 |
Median SBP (mmHg) | 150.0 (133.5–172.0) | 160.0 (139.0–186.0) | 0.003 | 150.0 (132.3–174.5) | 160.0 (140.0–185.8) | 0.03 | 146.5 (132.0–166.8) | 156.5 (140.0–177.8) | 0.08 | 151.7 (134.8–175.0) | 160.0 (139.3–185.8) | 0.09 | 150.0 (132.0–172.5) | 160.0 (140.0–186.0) | 0.004 |
Median DBP (mmHg) | 80.0 (70.0–90.0) | 80.0 (72.0–90.0) | 0.06 | 80.0 (70.0–90.0) | 80.0 (72.0–89.5) | 0.2 | 80.0 (70.0–86.0) | 80.0 (70.0–86.5) | 0.4 | 80.0 (70.0–89.0) | 80.0 (75.0–89.5) | 0.1 | 80.0 (70.0–90.0) | 80.0 (72.7–90.0) | 0.08 |
Median MAP (mmHg) | 102.3 (93.0–114.3) | 106.7 (96.7–120.0) | 0.007 | 103.3 (92.7–116.6) | 106.7 (96.7–118.1) | 0.05 | 100.2 (93.2–113.1) | 106.2 (96.6–118.0) | 0.2 | 103.3 (93.3–114.2) | 105.0 (96.8–120.5) | 0.08 | 103.3 (92.5–115.6) | 106.7 (96.7–120.0) | 0.01 |
MVD (%) | 70.4 | 78.6 | 0.05 | 73.6 | 82.0 | 0.08 | 71.7 | 73.5 | 0.8 | 75.2 | 85.3 | 0.08 | 72.7 | 81.6 | 0.04 |
CHF (%) | 17.4 | 29.0 | 0.001 | 20.6 | 32.0 | 0.01 | 19.6 | 26.5 | 0.4 | 21.5 | 27.9 | 0.3 | 19.9 | 30.4 | 0.01 |
FPE (%) | 5.4 | 11.0 | 0.01 | 6.3 | 11.0 | 0.1 | 6.5 | 8.8 | 0.6 | 7.0 | 10.3 | 0.4 | 6.1 | 10.4 | 0.09 |
Diabetes (%) | 31.4 | 31.0 | 0.9 | 32.3 | 33.0 | 0.9 | 34.1 | 35.3 | 0.9 | 36.0 | 23.5 | 0.06 | 32.3 | 29.6 | 0.6 |
RAB (%) | 49.9 | 50.3 | 0.9 | 43.5 | 46.0 | 0.6 | 41.3 | 44.1 | 0.8 | 51.7 | 47.1 | 0.5 | 46.5 | 48.0 | 0.8 |
BB (%) | 36.2 | 41.4 | 0.2 | 34.3 | 37.0 | 0.6 | 40.6 | 47.1 | 0.5 | 35.5 | 39.7 | 0.5 | 34.5 | 40.0 | 0.2 |
CaB (%) | 54.7 | 58.6 | 0.4 | 55.2 | 63.0 | 0.1 | 65.2 | 67.6 | 0.8 | 56.6 | 58.8 | 0.7 | 55.7 | 62.4 | 0.2 |
>3 anti-hypertensives (%) | 47.3 | 51.7 | 0.3 | 45.2 | 47.0 | 0.7 | 50.7 | 47.1 | 0.7 | 53.3 | 47.1 | 0.4 | 46.5 | 48.8 | 0.6 |
Aspirin (%) | 53.3 | 60.0 | 0.1 | 52.8 | 62.0 | 0.09 | 54.3 | 64.7 | 0.3 | 58.3 | 70.6 | 0.07 | 53.3 | 62.4 | 0.07 |
Statin (%) | 55.3 | 58.6 | 0.5 | 49.8 | 55.0 | 0.3 | 53.6 | 61.8 | 0.4 | 58.3 | 55.9 | 0.7 | 52.4 | 56.8 | 0.4 |
Median Proteinuria (g/day) | 0.6 (0.2–1.2) | 0.4 (0.2–1.1) | 0.3 | 0.6 (0.2–1.3) | 0.5 (0.2–1.2) | 0.2 | 1.0 (0.6–1.9) | 0.7 (0.3–1.4) | 0.1 | 0.6 (0.2–1.1) | 0.6 (0.2–1.1) | 0.4 | 0.6 (0.2–1.3) | 0.5 (0.2–1.1) | 0.1 |
Median eGFRa (ml/min/1.73 m2) | 29.9 (18.8–43.2) | 30.2 (20.0–43.4) | 0.7 | 27.2 (16.7–40.5) | 28.5 (17.3–37.7) | 0.9 | 16.0 (9.3–26.8) | 21.5 (10.3–30.5) | 0.2 | 29.9 (19.4–44.5) | 34.1 (23.0–45.4) | 0.2 | 27.4 (17.2–41.3) | 29.5 (19.6–40.1) | 0.3 |